Brand Name

Brilinta

Generic Name
Ticagrelor
View Brand Information
FDA approval date: August 05, 2011
Classification: P2Y12 Platelet Inhibitor
Form: Tablet

What is Brilinta (Ticagrelor)?

BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular death, myocardial infarction , and stroke in patients with acute coronary syndrome or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)

Summary: More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF). In this particular setting, balancing between the prevention of thrombosis and the risk of bleeding remains challenging. Oral anticoagulation (OAC) prevents stroke and systemic embolism, but has n...

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Summary: The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease

Summary: The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs. The main questions it aims to answer are: * Does the personalized plan lower the rate of blood clots in the treated leg one year after the proced...